GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (FRA:NB3) » Definitions » Institutional Ownership

Neurocrine Biosciences (FRA:NB3) Institutional Ownership : 60.53% (As of May. 25, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Neurocrine Biosciences Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Neurocrine Biosciences's institutional ownership is 60.53%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Neurocrine Biosciences's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Neurocrine Biosciences's Float Percentage Of Total Shares Outstanding is 85.39%.


Neurocrine Biosciences Institutional Ownership Historical Data

The historical data trend for Neurocrine Biosciences's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences Institutional Ownership Chart

Neurocrine Biosciences Historical Data

The historical data trend for Neurocrine Biosciences can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 64.57 64.50 63.95 61.23 61.66 61.90 62.34 61.50 60.75 60.53

Neurocrine Biosciences Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Neurocrine Biosciences (FRA:NB3) Business Description

Traded in Other Exchanges
Address
12780 El Camino Real, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Neurocrine Biosciences (FRA:NB3) Headlines

No Headlines